Scholarlink

<p>The accuracy of intraoperative tumor margin assessment is the main challenge in breast conserving surgery (BCS). NIR-II fluorescence-guided surgery enables surgeons to visualize the tumor margins dynamically in real time and facilitate the precision of tumor resection. We develop an aptamer-conjugated NIR-II probe for intraoperative fluorescence imaging. Peglated indocyanine green (PEG-ICG) was conjugated with an aptamer SYL3C binding to EpCAM to synthesize the probe SYL3C-ICG. Human breast cancer cell lines with different expression levels of EpCAM were employed to assess its tumor-targeting capability. Tumor xenograft models were established to investigate the in vivo selectivity of SYL3C-ICG, and a segmental excision procedure was employed to evaluate the efficacy of the probe in navigating precise surgical resection under NIR-II imaging. In vitro and in vivo fluorescence imaging revealed that NIR-II provides superior imaging resolution and penetration depth compared to NIR-I, and SYL3C-ICG could selectively accumulate at the tumor site, which helps surgeons detect tiny residual malignant lesions invisible to the naked eye and reduce the postoperative recurrence rate.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Aptamer-based NIR II imaging for breast cancer surgical resection

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月19日

查看全文
  • Lei Niu,
  • Kang-Liang Lou,
  • Zhi Zhu,
  • Wei-Zhi Liu,
  • Wen-Liang Gao,
  • Gu-Yue Hu,
  • Jun-Xue Gao,
  • Guo-Jun Zhang,
  • Wen-He Huang

摘要

The accuracy of intraoperative tumor margin assessment is the main challenge in breast conserving surgery (BCS). NIR-II fluorescence-guided surgery enables surgeons to visualize the tumor margins dynamically in real time and facilitate the precision of tumor resection. We develop an aptamer-conjugated NIR-II probe for intraoperative fluorescence imaging. Peglated indocyanine green (PEG-ICG) was conjugated with an aptamer SYL3C binding to EpCAM to synthesize the probe SYL3C-ICG. Human breast cancer cell lines with different expression levels of EpCAM were employed to assess its tumor-targeting capability. Tumor xenograft models were established to investigate the in vivo selectivity of SYL3C-ICG, and a segmental excision procedure was employed to evaluate the efficacy of the probe in navigating precise surgical resection under NIR-II imaging. In vitro and in vivo fluorescence imaging revealed that NIR-II provides superior imaging resolution and penetration depth compared to NIR-I, and SYL3C-ICG could selectively accumulate at the tumor site, which helps surgeons detect tiny residual malignant lesions invisible to the naked eye and reduce the postoperative recurrence rate.